Hepaitech (Beijing) Biopharma Technology Co. Ltd. has disclosed bile acids acting as farnesoid X receptor (FXR) and/or G-protein coupled bile...

Tetra Pharm Technologies Aps has announced promising results from preclinical testing of its pain-relieving drug, TPT-0301, which targets the endocannabinoid system.

An artificial intelligence (AI) framework developed by researchers in Denmark has outperformed human emergency call handlers in identifying stroke. The AI tool has the potential to play a critical role in helping to address the number of strokes that go unrecognized as the number of strokes are projected to increase as the population ages.

Vigil Neuroscience Inc. has synthesized heterocyclic compounds acting as triggering...

Eisai Co. Ltd. and Biogen Inc.’s Leqembi (lecanemab) gained the support of the U.S. FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (adcom) in a 6-0 vote on June 9, as panel members unanimously agreed that the results of the phase III Clarity trial verified the clinical benefit in the treatment of Alzheimer’s disease. The FDA does not have to follow the adcom’s recommendation, but it often does. The PDUFA date for the supplemental NDA is July 6.

Dtx Pharma Inc.’s Dtx-1252, an investigational small interfering RNA (siRNA) therapeutic, has been awarded U.S. orphan drug designation for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A).